Pfenex Inc. is a clinical stage biotechnology company. The company develops biosimilar therapeutics and high-value/difficult to manufacture proteins using its Pfenex Expression Technology platform. The company’s lead product candidate is a biosimilar to Lucentis (ranibizumab), a treatment for retinal diseases. The company’s developmental pipeline includes biosimilar product candidates as well as generic and vaccine candidates.